FDA Approves Inhaled Form Of Insulin
The Food and Drug Administration (FDA) has approved a long-delayed inhalable diabetes medication to help patients control their blood sugar levels during meals.
The FDA cleared MannKind Corp.’s Afrezza, a fast-acting form of insulin, for adults with the most common form of diabetes, which affects more than 25 million Americans. Friday’s approval comes more than three years after the agency first asked MannKind to run additional clinical studies on the drug.
Category: News